These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 6764836)

  • 21. Different functions of subsets of effector T cells in murine influenza virus infection.
    Leung KN; Ada GL
    Cell Immunol; 1982 Mar; 67(2):312-24. PubMed ID: 6979396
    [No Abstract]   [Full Text] [Related]  

  • 22. Induction of leukemia regression in mice by immunotherapeutic transfer of T-lymphocytes.
    Johnson CS; Thurlow SM; Furmanski P
    Cancer Res; 1986 Jan; 46(1):183-9. PubMed ID: 3079585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden.
    Awwad M; North RJ
    Immunology; 1988 Sep; 65(1):87-92. PubMed ID: 2972604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells.
    Shu S; Rosenberg SA
    J Immunol; 1985 Oct; 135(4):2895-903. PubMed ID: 2411817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirement for T cells.
    Berenson JR; Einstein AB; Fefer A
    J Immunol; 1975 Jul; 115(1):234-8. PubMed ID: 1080165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapy of disseminated tumors by adoptive transfer of specifically immune T cells.
    Greenberg PD; Klarnet JP; Kern DE; Cheever MA
    Prog Exp Tumor Res; 1988; 32():104-27. PubMed ID: 3287447
    [No Abstract]   [Full Text] [Related]  

  • 27. [The cytotoxic activity of tumor infiltrating lymphocytes (TIL) and its application to adoptive immunotherapy].
    Hori T; Kan N; Yamasaki N; Nakayama N; Nio Y; Inamoto T; Ohgaki K; Kodama H
    Nihon Gan Chiryo Gakkai Shi; 1985 Jun; 20(5):943-53. PubMed ID: 3877130
    [No Abstract]   [Full Text] [Related]  

  • 28. Cloned helper and cytotoxic T lymphocytes as effector cells in adoptive immunotherapy of murine leukemia.
    Bookman MA; Horak E; de Graaf PW
    Prog Clin Biol Res; 1989; 288():141-9. PubMed ID: 2524069
    [No Abstract]   [Full Text] [Related]  

  • 29. Cells mediating graft rejection in the mouse. IV. The Ly-5, 6, and 8 effector cell phenotype.
    Loveland BE; McKenzie IF
    Transplantation; 1982 Apr; 33(4):411-3. PubMed ID: 6978559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Specificity of the T cells that mediate and suppress adoptive immunotherapy of established tumors.
    Dye ES; North RJ
    J Leukoc Biol; 1984 Jul; 36(1):27-37. PubMed ID: 6234371
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The therapeutic significance of concomitant antitumor immunity. II. Passive transfer of concomitant immunity with Ly-1+2- T cells primes established tumors in T cell-deficient recipients for endotoxin-induced regression.
    North RJ
    Cancer Immunol Immunother; 1984; 18(2):75-9. PubMed ID: 6391656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models.
    Reissmann T; Voegeli R; Pohl J; Hilgard P
    Cancer Immunol Immunother; 1989; 28(3):179-84. PubMed ID: 2924329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The acute inflammatory process in murine lymphocytic choriomeningitis is dependent on Lyt-2+ immune T cells.
    Dixon JE; Allan JE; Doherty PC
    Cell Immunol; 1987 Jun; 107(1):8-14. PubMed ID: 3495350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ontogeny of T-cell function: alloreactivity appears earlier than reactivity against hapten-modified self and interleukin-2 production.
    Stutman O; Ishizaka ST
    Clin Immunol Immunopathol; 1982 May; 23(2):202-14. PubMed ID: 6213338
    [No Abstract]   [Full Text] [Related]  

  • 35. Effector phenotype and immunologic specificity of T-cell-mediated adoptive therapy for a murine tumor that lacks intrinsic immunogenicity.
    Sakai K; Chang AE; Shu S
    Cell Immunol; 1990 Aug; 129(1):241-55. PubMed ID: 2364440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adoptive immunotherapy of a syngeneic murine leukemia with a tumor-specific cytotoxic T cell clone and recombinant human interleukin 2: correlation with clonal IL 2 receptor expression.
    Matis LA; Shu S; Groves ES; Zinn S; Chou T; Kruisbeek AM; Rosenstein M; Rosenberg SA
    J Immunol; 1986 May; 136(9):3496-501. PubMed ID: 2420893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells.
    North RJ; Bursuker I
    J Exp Med; 1984 May; 159(5):1295-311. PubMed ID: 6232335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mouse leukemia: therapy with monoclonal antibodies against a thymus differentiation antigen.
    Bernstein ID; Tam MR; Nowinski RC
    Science; 1980 Jan; 207(4426):68-71. PubMed ID: 6965328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.
    Cheever MA; Greenberg PD; Fefer A; Gillis S
    J Exp Med; 1982 Apr; 155(4):968-80. PubMed ID: 6977616
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adoptive cellular immunotherapy of human ovarian carcinoma xenografts in nude mice.
    Ortaldo JR; Porter HR; Miller P; Stevenson HC; Ozols RF; Hamilton TC
    Cancer Res; 1986 Sep; 46(9):4414-9. PubMed ID: 3089592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.